AdvanCell raised a $315 million Series D round to accelerate late-stage development of its radiopharmaceutical program and to expand manufacturing and isotope capabilities. The financing supports the company’s push toward Phase 3 for ADVC-001, a lead-212 PSMA-targeted radioligand for metastatic castration-resistant prostate cancer, positioning it as an integrated radiopharma platform.